75 questions that clarify health-commerce websites.

A compounded drug is prepared for an individual patient or a defined care setting under applicable compounding rules. It is not the same as an FDA-approved drug product, and the specific pathway and conditions matter.

Section 503A generally applies to qualifying compounding by a state-licensed pharmacy, federal facility, or licensed physician that is not an FDA-registered outsourcing facility. A core condition is a valid prescription for an identified individual patient, subject to the statute and FDA guidance.

Section 503B applies to a qualifying outsourcing facility that elects to register with FDA and meets the applicable conditions. FDA describes outsourcing facilities as subject to current good manufacturing practice requirements.

No. The 503A and 503B provisions can provide specified exemptions when their conditions are met; they do not make a compounded drug an FDA-approved drug product.

503A is generally tied to patient-specific compounding by qualifying pharmacies, federal facilities, or physicians. A qualifying 503B outsourcing facility may compound without patient-specific prescriptions, subject to its separate statutory conditions and other applicable law.

The general framework is patient-specific. Limited anticipatory compounding may be permitted in defined circumstances, but it is not a blanket license for large-scale production or broad distribution. The pharmacy and qualified counsel should assess the actual model.

A qualifying 503B outsourcing facility may compound without patient-specific prescriptions, including for office-use arrangements, subject to section 503B and other applicable requirements. The clinic must confirm its specific ordering, storage, state, and distribution model.

No. FDA registration of an outsourcing facility is not approval of every compounded product or a quality guarantee. Product-specific and facility-specific diligence remains necessary.

FDA maintains and develops lists and policies addressing bulk drug substances that may be used in compounding under 503A and 503B. The applicable list and status can differ by pathway and can change.

Both frameworks restrict compounding products that are essentially copies in many circumstances. Shortage status and other statutory conditions can affect the analysis, so this must be reviewed for the specific product and timing.

No. Shortage status is relevant to certain rules, but it does not eliminate every condition, restriction, state-law issue, or product-specific requirement.

Qualified clinicians operating within the approved clinical workflow determine eligibility and treatment decisions. A website, checkout page, or marketing funnel should not promise approval.

Use precise, non-promissory language that reflects the real clinical and pharmacy workflow. Avoid describing a compounded product as FDA-approved, guaranteed available, or appropriate for every person.

No. A commerce page can explain a program and route a person to the approved next step. It should not replace the clinical evaluation, prescription, consent, or medical record process.

Start with current FDA materials, then have the pharmacy, qualified regulatory counsel, and clinical leadership review the exact ingredient, dosage form, states, patient flow, and public claims before launch.

No. “Peptide” is a broad scientific and marketing term. The exact substance, dosage form, source, intended use, regulatory category, and current FDA rules determine the relevant analysis.

No. A 503A or 503B label is not blanket permission for every substance. The ingredient and product must be evaluated against the applicable statutory conditions, FDA lists and policies, and state requirements.

FDA states that biological products are not eligible for the exemptions for compounded drugs under sections 503A and 503B. Do not assume a product fits a compounding pathway merely because it is called a peptide.

Not unless referring precisely to an FDA-approved product and its approved labeling. A compounded product should not be marketed as FDA approved.

An ingredient name identifies what a product is described as containing. A product claim says what it does, who it is for, or what outcome is expected. Claims require a separate, careful substantiation and regulatory analysis.

No broad promise is safe. Availability can depend on clinician determination, pharmacy inventory, current rules, state restrictions, and the actual dispensing workflow.

No. Prescription and treatment decisions belong to qualified clinicians. Website language should make the clinical review and potential eligibility limits clear.

Define what is actually being paid for, when the clinical review occurs, who handles the prescription and fulfillment, what happens if a person is not eligible, and who owns refund, cancellation, and support questions.

Only if the approved clinical, privacy, and technology workflow supports it. In many cases, a public marketing site should route a person into the designated clinical intake environment rather than store sensitive clinical information itself.

Do not make “same as,” interchangeability, superiority, or equivalence claims without qualified legal and regulatory review. The comparison can create misleading expectations and additional compliance risk.

A “research use only” label does not make a product appropriate for human marketing or treatment. A healthcare website should not use it as a workaround for a product or claim that needs another legal pathway.

No. A certificate of analysis may be relevant to a supplier or ingredient-quality process, but it does not answer the full product, pharmacy, clinical, dispensing, state-law, or marketing-compliance question.

Use extreme caution. Testimonials and images can imply outcomes, typicality, or medical claims. Have qualified review of the exact representation, disclosures, patient authorization, and platform policies before publication.

The answer should be defined in the operating model. Clinics, providers, pharmacies, and technology partners have distinct responsibilities; the website must route patients clearly without having non-clinical staff answer clinical questions.

Explain the process rather than promise a product or result: qualified clinical review, eligibility determination, pharmacy fulfillment where applicable, and real support contacts for the next step.

FDA regulates dietary supplements as a category of food, not as prescription drugs. The category has its own labeling, manufacturing, and claim rules.

Generally, no. Dietary supplements are not approved by FDA in the same way as new drugs before they are marketed, although manufacturers and distributors remain responsible for meeting applicable requirements.

It is a claim describing the role of a nutrient or dietary ingredient intended to affect normal structure or function in humans, or characterizing a documented mechanism by which it acts to maintain that structure or function.

No. FDA says these claims are not pre-approved, but the responsible firm must have substantiation that the claim is truthful and not misleading and must meet applicable notification and disclaimer requirements.

The law requires a specified disclaimer on labels when applicable: that the statement has not been evaluated by FDA and the product is not intended to diagnose, treat, cure, or prevent any disease. Use qualified counsel to confirm the exact required presentation.

Disease claims can cause a product to be regulated as a drug. Do not publish disease-treatment, cure, prevention, or therapeutic claims without qualified regulatory review.

No. Soft verbs do not solve a claim problem. The full context, imagery, testimonials, ingredient discussion, audience, and implied outcome matter.

Substantiation is the support a responsible firm has for a claim. The appropriate evidence depends on the exact claim; marketing copy should not outpace the evidence or legal review.

Yes, endorsements can communicate claims, including implied claims. A testimonial does not make an otherwise unsupported or disease-oriented claim acceptable.

No. Claims made in blog posts, ads, social media, email, video, and product pages can all affect how the product is represented.

The product’s identity, ingredients, amount of dietary ingredients, serving information, business details, and other labeling requirements must be handled accurately. Use qualified label review before production or site publication.

Yes. This is a high-risk, specific claim. It needs support that matches the exact product, ingredient form, dosage, population, and promised outcome—not a loose reference to unrelated research.

Avoid wording that presents a supplement as diagnosing, treating, curing, preventing disease, or functioning like a prescription product. The product category and claims must stay aligned.

Claims, substantiation, disclaimers, Supplement Facts and label accuracy, testimonials, before-and-after content, ad copy, subscriptions, refunds, and every linked landing page or email flow.

The responsible brand should use qualified regulatory and legal review, with science and marketing aligned. ToolBX can structure the site and flag claim-risk patterns; it does not provide legal approval.

LegitScript describes its Healthcare Certification program as a review against its certification standards for eligible healthcare merchants. It is separate from government licensure, clinical approval, or FDA drug approval.

No. LegitScript makes its own certification decisions under its standards and terms. ToolBX can provide readiness support, but neither ToolBX nor a website build can guarantee certification.

Healthcare businesses may pursue it for payment, advertising, platform, or risk-management requirements. The applicable requirement depends on the merchant type, services, processor, platform, and jurisdiction.

No. LegitScript’s standards address more than a website, including areas such as licensure, business registration, and legal/regulatory compliance. The full operating business is reviewed.

Accurate business identity and contact details, services and product information, clinical/provider disclosures where applicable, pharmacy and fulfillment disclosures, privacy/terms/refund policies, licensing information, and a clear patient or customer path.

No. The website should accurately explain the responsible parties and the flow of care, prescribing, dispensing, fulfillment, and support where applicable.

No. Do not imply current certification, approval, partnership, or endorsement unless it is true and you have the right to use the relevant mark.

No. Certification does not replace business, professional, pharmacy, or other required licenses and registrations.

No. Certification does not make misleading, unsupported, or noncompliant claims acceptable. Marketing content still requires its own review.

Missing business identity, vague provider/pharmacy roles, inaccurate claims, incomplete policies, unclear patient support, contradictory pricing, broken links, misleading testimonials, or a flow that does not match operations.

Treat material changes as a compliance review point. Update disclosures and policies, check the actual flow, and confirm whether the applicable certification, payment, advertising, pharmacy, or legal stakeholders require notice or review.

ToolBX can provide website and readiness support within an agreed scope. The applicant is responsible for accurate information and the certification authority makes the decision.

No. Merchant approval and payment processing are decided by the relevant acquirer, processor, bank, card network, or platform under their own underwriting and policies.

No. Advertising platforms make their own policy and account decisions. Certification may be relevant to a platform’s requirements, but it is not a guaranteed advertising outcome.

Map the actual business, clinical, pharmacy, payment, and support responsibilities; audit every public claim and policy; repair inconsistencies; collect documentation; then apply only when the operating reality and public site agree.

No. The right choice depends on the approved commerce model, clinical handoff, payment path, content needs, integrations, privacy boundaries, operations, and team capacity.

Shopify can be a strong fit when the business needs product merchandising, subscriptions, a standardized commerce checkout, catalog management, and an ecosystem of commerce integrations.

WordPress can be a strong fit when the business needs flexible content architecture, service and education pages, custom information flows, complex SEO content, or a tailored front-end experience.

Shopify can support the commercial layer, but a clinical intake should live in an approved clinical workflow or integration when it handles sensitive health information. Do not assume a standard Shopify form is the right place for clinical data.

No. WordPress is a content-management system, not automatically an electronic medical record. The clinic must determine where clinical information belongs and use approved systems and controls.

No. A website platform can present the public experience and support defined handoffs. It does not by itself provide clinical screening, provider services, medical records, or patient support operations.

Shopify is often efficient for conventional ecommerce subscriptions. The best fit for a health-related program depends on the product, billing model, merchant approval, clinical sequence, patient communication, and required integrations.

Shopify supports checkout extensibility and app-based extensions, but checkout behavior is governed by the platform’s current architecture and plan/app capabilities. Confirm the exact requirement before promising a custom payment or intake experience.

Yes. WooCommerce can support product, cart, checkout, and subscription workflows with appropriate configuration and integrations. That flexibility also creates more implementation, security, performance, and maintenance responsibility.

Both can support strong SEO when pages are fast, useful, crawlable, structured, internally linked, and maintained. WordPress is often more flexible for editorial publishing; Shopify can still support robust content when the information architecture is deliberate.

Either can work. The decision should follow conversion needs, speed, tracking, existing stack, lead routing, and what must happen after the click—not a platform preference alone.

Usually not. The real system may include the website, checkout, CRM, messaging, scheduling, clinical platform, EMR, pharmacy, analytics, payment processor, and patient-support team.

Ask what information the page truly needs, where it will be stored, who can access it, and whether the approved clinical and privacy workflow is ready to receive it. Keep sensitive clinical data out of general marketing tools unless the actual compliant model permits it.

What is the next legitimate action: learn, book, complete approved intake, pay for a defined service, buy a product, or speak with support? Build the platform and page around that one clear step.

The offer, audience, content requirements, clinical and data boundaries, handoffs, payment/merchant model, integrations, support ownership, tracking plan, launch sequence, and who maintains the system after launch.